Sparsentan (2) – Filspari®
Immunoglobulin A nephropathy, primary
Characteristics
| Start date | 15.10.2026 |
|---|---|
| Resolution | 15.04.2027 – active procedure |
| INN | Sparsentan |
| Brand name | Filspari® |
| Pharm. company | Vifor Pharma Deutschland GmbH |
| G-BA Procedure ID | D-1380 |
| Therapeutic area | Genitourinary system diseases Orphan (turnover limit) |
| Reason for procedure | Reassessment: Orphan turnover exceeded |
Associated procedures
| Sparsentan (2) | Filspari® | Vifor Pharma Deutschland GmbH | Immunoglobulin A nephropathy, primary | n.d. | active procedure Orphan (turnover limit) | |
| Sparsentan (1) | Filspari® | Vifor Pharma Deutschland GmbH | Immunoglobulin A - Nephropathy, primary | 900–13,000 | 100% Hint for minor additional benefit Orphan |
<< List of all resolutions